Ilyang to enter Phase I/II studies for new investigational leukemia drug

Published: 2008-06-13 06:57:00

Updated: 2008-06-13 06:57:00

Ilyang Pharm says it will conduct Phase I and II trials simultaneously for its new leukemia medicine “IY5511” in 10 hospitals at home and abroad for 18 months, after getting the IND approval from the Korea Food and Drug Administration.

“Based on the positive results of preclinical studies, IY5...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK